50 Years of Monoclonal Antibody Technology: What’s Next?
Post Date: November 20, 2025 | Publish Date:
Genentech’s Andy Chan discussed rapidly evolving immune-based therapies for Cincinnati Children’s Envisioning Our Future for Children speaker series.
Cincinnati Children’s welcomed Andy Chan, MD, PhD, senior vice president of Research Biology at Genentech, for the latest installment of the Envisioning Our Future For Children speaker series. Chan’s presentation, “50 Years of Monoclonal Antibody Technology: Past, Present and Future,” traced the arc of antibody engineering from its 1970s origins to today’s rapidly evolving landscape of synthetic immunity, reverse translation, CAR T, and in vivo cell programming.
Chan noted that 2025 marks the fifth decade anniversary of the discovery of monoclonal antibodies and emphasized that the field’s evolution has not been linear but driven by technological leaps paired with forward and reverse translation between lab and clinic.
“As a discovery researcher, you always want to build new discoveries and take observations from bench to bedside,” he said. “But just as importantly, we must learn from our human experience in clinical trials.”
Today, he said, the most exciting advances emerge from convergence—multi-omics, functional genomics, AI-enabled analysis, and an expanding set of drug modalities.
“This is a phenomenally exciting time. It’s the convergence of orthogonal technologies that will enable the next generation of therapeutics,” he said.
Watch the full recording above to learn more about Chan’s vision for a future filled with new modalities and data-driven design, and view other past talks at envisioningourfuture.org.
Don’t Miss a Post:
- Subscribe to the Research Horizons Newsletter
- Follow Cincinnati Children’s Research Foundation on Bluesky, X and LinkedIn
Latest Posts
About this blog
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment. Email researchnews@cchmc.org with questions or ideas.
Subscribe to Our Newsletter